A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions

Age-Related Macular Degeneration

Interventions

DRUG

MG-O-1002

MG-O-1002 ophthalmic solution in one concentration (0.8%) ocular administration 3 drops in study eye

OTHER

Placebo

The placebo is 0.9% saline ocular administration 3 drops in study eye

Trial Locations (6)

RECRUITING

Rajavithi Hospital, Bangkok

RECRUITING

Ramathibodi Hospital, Bangkok

RECRUITING

Srinagarind Hospital, Khon Kaen

RECRUITING

Metta Pracharak Hospital, Nakhon Pathom

RECRUITING

Thammasat University Hospital, Pathum Thani

RECRUITING

Naresuan University Hospital, Phitsanulok

All Listed Sponsors

lead

Theratocular Biotek Co.

INDUSTRY